In September 2020, the FDA granted accelerated approval for pralsetinib to treat adult patients with metastatic fusion RET positive NSCLC, and on December 2020, for advanced or metastatic medullary thyroid cancer with genetically defective RET [217]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.